The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-23. Anything still debated is marked as such rather than presented as settled.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
== Personal life == Since his playing career ended, Bagwell has spent much of his time with his family while sporadically taking coaching and special assignment positions for the Astros. He is married to Rachel Bagwell, his third wife, with whom he has five children in a blended family. Rachel had three children prior to meeting Jeff. Before his marriage to Rachel, Jeff had two daughters, Blake and Bryce. Bagwell married his first wife, model Shaune Bagwell (née Stauffer), in 1992. He later married Ericka Bagwell, with whom he had his two daughters. Rachel Bagwell was the widow of Greater Houston-area hand surgeon Dr. Michael Brown, the owner and founder of Brown Hand Center. In spite of his professional success, Bagwell has stated that he "doesn't enjoy too much of the spotlight" that follows. While giving a tribute to him during the retirement ceremony of his uniform number, longtime friend and former teammate Brad Ausmus noted several little-known facts. "He liked soccer as much as ... baseball" while growing up in Connecticut. He hit three fewer home runs than his boyhood idol, Carl Yastrzemski, who hit 452. "His baseball card says he's six feet tall. He's closer to 5' 10"." Both Bagwell and Ausmus hit 32 triples in their careers. After his playing career, Bagwell was seen with significantly longer hair. Remarked Ausmus, "I want to confirm he does not have hair extensions." In January 2015, Bagwell reportedly sold his home in the Memorial neighborhood of Houston.
In many histological preparations of the submandibular gland, the serous acinar cells located in the hybrid seromucous acini are pushed out from between the mucous acinar cells, and appear as crescent-shaped demilunes located at the back of the acini. This fixation artifact can be avoided by rapid-freezing fixation.
Life expectancy of people with acromegaly is dependent on how early the disease is detected. Life expectancy after the successful treatment of early disease is equal to that of the general population. Acromegaly can often go on for years before diagnosis, resulting in poorer outcome, and it is suggested that the better the growth hormone is controlled, the better the outcome. Upon successful surgical treatment, headaches and visual symptoms tend to resolve. One exception is sleep apnea, which is present in around 70% of cases but does not tend to resolve with successful treatment of growth hormone level. While hypertension is a complication of 40% of cases, it typically responds well to regular regimens of blood pressure medication. Diabetes that occurs with acromegaly is treated with the typical medications, but successful lowering of growth hormone levels often alleviates symptoms of diabetes. Hypogonadism without gonad destruction is reversible with treatment. Acromegaly is associated with a slightly elevated risk of cancer.
With the development of AMS in the 1980s it became possible to measure these isotopes precisely enough for them to be the basis of useful dating techniques, which have been primarily applied to dating rocks. Naturally occurring radioactive isotopes can also form the basis of dating methods, as with potassium–argon dating, argon–argon dating, and uranium series dating. Other dating techniques of interest to archaeologists include thermoluminescence, optically stimulated luminescence, electron spin resonance, and fission track dating, as well as techniques that depend on annual bands or layers, such as dendrochronology, tephrochronology, and varve chronology.
1 by the Secretary of State for Home Affairs 2 by the London County Council 1 by the Corporation of the City of London 2 (jointly) by the councils of the metropolitan boroughs of the County of London 1 (jointly) by the county councils of Buckinghamshire, Essex, Hertfordshire, Middlesex 1 (jointly) by the county councils of Kent and Surrey 1 (jointly) by the corporations of the county boroughs of Croydon, East Ham, West Ham 1 representative of the Metropolitan Police, appointed by the Secretary of State for Home Affairs 1 representative of the City of London Police appointed by the City Corporation 1 appointed by the Minister of Transport The members of the committee were to appoint a chairman themselves.
Sources: en.wikipedia.org
“At some point, we will probably also have to pay for the embezzlement of the Itaipu Retirement Fund (Cajubi), which is another case, and that's because there isn't a public entity that is constitutionally obligated to do so,” he stated. On December 14, 2023, Peña enacted Law 7253/23, creating the Superintendency of Retirements and Pensions in Paraguay.
== Toxicity == Activation of Ppk1/Ppk26 induces rolling — typical nociceptive behavior in Drosophila larvae. However, no information is available regarding the lethal dose of Do6a toxin. One sting of a velvet ant is not lethal to praying mantis or mouse but is deadly for the honeybee. It is important to remember that velvet ant venom comprises other toxins apart from Do6a.
Further testing in a microfluidic blood vessel model lined with human endothelial cells showed that pNPs triggered a self-amplifying coagulation-like process, forming nanofibrous structures that occluded sections of the artificial vessel. These findings suggest that pNPs could serve as a synthetic alternative for enhancing clot formation and improving hemorrhage management in trauma care.
GnRH antagonists have an immediate onset of action leading to a fast and profound suppression of testosterone and are therefore especially valuable in the treatment of patients with prostate cancer, where fast control of disease is needed. The GnRH antagonist abarelix was withdrawn from the United States market in 2005 and is now only marketed in Germany for use in patients with symptomatic prostate cancer. Degarelix is a GnRH antagonist that is approved for use in patients with advanced hormone-sensitive prostate cancer throughout Europe and also in the United States.
== Early life and education == Stansbury was born in Farmington, New Mexico, and raised in Albuquerque. After graduating from Cibola High School in 1997, she received a Bachelor of Arts degree in human ecology and natural science from Saint Mary's College of California in 2002. She then received a Master of Science degree in development sociology with a minor in American Indian studies from Cornell University in 2007, where she was a PhD candidate.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.